Curtana Pharmaceuticals is advancing a novel, dual-action therapy designed to halt recurrence by eradicating cancer stem cells and reversing tumor-driven immune suppression in adults and pediatric brain cancers.
At Curtana Pharmaceuticals, we are driven by an urgent mission to develop life-changing therapies for patients facing the most devastating central nervous system (CNS) malignancies. Standard treatments often leave behind resilient cancer stem cells – the true source of disease recurrence. Our lead investigational therapy, CT-179, is a potent, orally available, CNS-penetrant small-molecule inhibitor targeting OLIG2 (pronounced OH-lig-two), a master transcription factor that is at the source of many types of brain cancer. By dismantling tumor architecture at its source and reawakening the body’s innate defenses, we are committed to changing the treatment paradigm.
Adult Program
Safety, Tolerability, and MTD
When GBM inevitably returns following frontline standard-of-care, the disease is exceptionally aggressive and highly resistant to further conventional treatments. In this recurrent setting, clinical options are severely limited, and median survival drops drastically to approximately 6 to 9 months. This devastating cycle of relapse is driven by a highly resilient subpopulation of cancer stem cells (CSCs) that survive initial surgical and chemoradiation interventions. These residual CSCs rely heavily on the OLIG2 transcription factor to rebuild the tumor architecture and actively suppress the immune microenvironment. Because addressing this resistance is our most immediate clinical priority, Recurrent GBM is the foundational indication for the dose-escalation phase of our ongoing OPAL Trial. By utilizing CT-179 to precisely target OLIG2, we aim to dismantle the cellular engine of recurrence, reverse tumor-driven immune evasion, and offer a powerful new therapeutic avenue for patients who have exhausted standard therapies.
Adult Program
Combo with Radiation Therapy
The most common and lethal primary adult brain tumor. There are approximately 30,000 to 40,000 new cases diagnosed annually across major global markets. Despite maximum surgical resection, radiation, and chemotherapy, recurrence is nearly universal. The median overall survival is approximately 14 to 16 months, with a 5-year survival rate of less than 10%. Furthermore, a significant portion of GBM patients have an MGMT-unmethylated status, rendering their tumors inherently resistant to standard chemotherapy. By targeting OLIG2, we aim to eliminate the cancer stem cells driving recurrence and sensitize tumors to radiation and immune attack.
February 2, 2026
Preclinical Study Reveals that CT-179 Remodels the Tumor Microenvironment – Turning “Cold” Tumors “Hot” – and Significantly Enhancing the Efficacy of Immune Checkpoint Inhibitors. Austin, TX – February 2, 2026 – Curtana Pharmaceuticals, a clinical-stage biotechnology company focused on improving outcomes for brain cancer patients, today announced the publication of a pivotal new study in…
January 14, 2026
February 4, 2025
Curtana Pharmaceuticals Announces Breakthrough in Pediatric Brain Cancer Treatment with Dual Studies Published in Nature Communications